Wound Debridements for Injuries with MCC DRG Reimbursement

Summary & Overview

Wound Debridements for Injuries with MCC: Inpatient Reimbursement Overview

DRG 901 encompasses inpatient admissions for wound debridements for injuries when a Major Complication or Comorbidity is present, addressing severe tissue loss, infection, or contamination that increases resource needs. Proper classification to this Diagnosis-Related Group matters for inpatient reimbursement because the Major Complication or Comorbidity elevates payment relative to less complex wound debridement cases under the Centers for Medicare & Medicaid Services inpatient prospective payment rules.

Wound DebridementDRG Wound Debridements for Injuries with MCCDRG 901Diagnosis-Related GroupInpatient ReimbursementMedicareSurgeryTraumaInfectious Disease

DRG 901 Overview

DRG 901 covers inpatient hospital admissions for wound debridements related to injuries when a Major Complication or Comorbidity is present, typically involving severe tissue damage, contamination, or infection requiring operative or extensive bedside debridement. This Diagnosis-Related Group groups cases where the presence of a Major Complication or Comorbidity drives higher resource use, such as longer length of stay, intensive wound care, and additional surgical or medical management. For Medicare payment, classification to this Diagnosis-Related Group affects relative weight and payment level within the inpatient prospective payment system. Accurate clinical documentation of the injury, extent of debridement, and the Major Complication or Comorbidity is essential to support assignment to this Diagnosis-Related Group.

National Payment Rates

Across commercial payers the reported rates for DRG 901 range roughly from $370 up to $160K, with median/p50 values spanning from about $37K to $76K depending on payer. The widest spread appears for Anthem (min $390 to max $160K), indicating the largest payer-level variability. See the table and chart below for payer-specific distributions and percentiles.

Mean Rates by Payer — National — DRG 901

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported in the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 901. These values summarize nationwide Medicare payment and charge levels for the reported discharges.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Across payers in Alaska for DRG 901, observed rates range from a low of $7.5K up to $180K, with mean values clustering at $60K for BCBS and Anthem and $100K for Cigna. The most notable deviation from national averages is Cigna’s substantially higher mean ($100K) versus typical national means, while BCBS/Anthem sit below national benchmarks. See the table and chart below for detailed distribution by payer.

Key Insights for Alaska

Highest payer: Cigna with a mean of $100K; Lowest payers: BCBS and Anthem tied with a mean of $60K.
Alaska shows a wide rate range from $7.5K to $180K across payers; Cigna’s mean of $100K meaningfully exceeds national means for major payers, while BCBS/Anthem are below national averages.

Clinical Trials

Acute operative technique and timing trials: Studies comparing immediate versus delayed surgical debridement strategies, or different operative debridement techniques (for example serial sharp debridement versus tangential/plastic surgery approaches) in patients with traumatic or complex soft tissue wounds and concomitant major complications. These trials enroll inpatients with varying wound severity and comorbidities (including infection, ischemia, or polytrauma) to evaluate short-term outcomes such as infection control, need for reoperation, limb salvage, and length of stay. Results inform surgeons and hospital payers about interventions that may reduce intensive resource utilization and complications in this high-MCC cohort.
Comparative effectiveness research on adjunctive wound therapies during inpatient care: Randomized or pragmatic studies comparing adjuncts to standard debridement (for example negative pressure wound therapy, biologic dressings, or topical antimicrobial protocols) in patients with complex, infected, or chronicized traumatic wounds that meet MCC criteria. These studies focus on wound healing trajectories, rates of secondary infection, required number of operating room returns, and inpatient resource use across diverse patient subgroups (diabetes, peripheral vascular disease, immunosuppression). Findings help care teams and payers evaluate which adjuncts produce meaningful improvements in clinically relevant outcomes and may justify higher initial inpatient costs through downstream savings.
Post-discharge outcomes and care transition studies: Prospective cohort studies or transitional care trials that follow patients after inpatient debridement with MCC-level complications to assess readmission rates, outpatient wound healing, functional recovery, and long-term costs of care. These studies target patients discharged to home, skilled nursing, or home health services to identify predictors of poor recovery (residual infection, nonhealing tissue, need for reconstructive surgery) and to test care coordination models that might reduce readmissions. Evidence from these studies is critical for hospitals and payers to design discharge planning, bundle payments, and post-acute pathways that lower avoidable utilization and improve patient-centered outcomes.

Related Codes

914-TRAUMATIC-INJURY-WITHOUT-MCC

Traumatic Injury without MCC: Inpatient Reimbursement Overview

909-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITHOUT-CC-MCC

Other O.R. Procedures for Injuries without CC/MCC: Inpatient Reimbursement Overview

918-POISONING-AND-TOXIC-EFFECTS-OF-DRUGS-WITHOUT-MCC

Poisoning and Toxic Effects of Drugs without MCC: Inpatient Reimbursement Overview

921-COMPLICATIONS-OF-TREATMENT-WITHOUT-CC-MCC

Complications of Treatment without CC/MCC: Inpatient Reimbursement Overview

906-HAND-PROCEDURES-FOR-INJURIES

Hand Procedures for Injuries: Inpatient Reimbursement Overview

923-OTHER-INJURY-POISONING-AND-TOXIC-EFFECT-DIAGNOSES-WITHOUT-MCC

Other Injury, Poisoning and Toxic Effect Diagnoses without MCC: Inpatient Reimbursement Overview

915-ALLERGIC-REACTIONS-WITH-MCC

Allergic Reactions with MCC: Inpatient Reimbursement Overview

902-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITH-CC

Wound Debridements for Injuries with CC: Inpatient Reimbursement Overview

907-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-MCC

Other O.R. Procedures for Injuries with MCC: Inpatient Reimbursement Overview

917-POISONING-AND-TOXIC-EFFECTS-OF-DRUGS-WITH-MCC

Poisoning and Toxic Effects of Drugs with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 19

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$46K	$190K	$39K	910

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 901

Key Insights for Alaska

Highest payer: Cigna with a mean of $100K; Lowest payers: BCBS and Anthem tied with a mean of $60K.
Alaska shows a wide rate range from $7.5K to $180K across payers; Cigna’s mean of $100K meaningfully exceeds national means for major payers, while BCBS/Anthem are below national averages.

Clinical Trials

Acute operative technique and timing trials: Studies comparing immediate versus delayed surgical debridement strategies, or different operative debridement techniques (for example serial sharp debridement versus tangential/plastic surgery approaches) in patients with traumatic or complex soft tissue wounds and concomitant major complications. These trials enroll inpatients with varying wound severity and comorbidities (including infection, ischemia, or polytrauma) to evaluate short-term outcomes such as infection control, need for reoperation, limb salvage, and length of stay. Results inform surgeons and hospital payers about interventions that may reduce intensive resource utilization and complications in this high-MCC cohort.
Comparative effectiveness research on adjunctive wound therapies during inpatient care: Randomized or pragmatic studies comparing adjuncts to standard debridement (for example negative pressure wound therapy, biologic dressings, or topical antimicrobial protocols) in patients with complex, infected, or chronicized traumatic wounds that meet MCC criteria. These studies focus on wound healing trajectories, rates of secondary infection, required number of operating room returns, and inpatient resource use across diverse patient subgroups (diabetes, peripheral vascular disease, immunosuppression). Findings help care teams and payers evaluate which adjuncts produce meaningful improvements in clinically relevant outcomes and may justify higher initial inpatient costs through downstream savings.
Post-discharge outcomes and care transition studies: Prospective cohort studies or transitional care trials that follow patients after inpatient debridement with MCC-level complications to assess readmission rates, outpatient wound healing, functional recovery, and long-term costs of care. These studies target patients discharged to home, skilled nursing, or home health services to identify predictors of poor recovery (residual infection, nonhealing tissue, need for reconstructive surgery) and to test care coordination models that might reduce readmissions. Evidence from these studies is critical for hospitals and payers to design discharge planning, bundle payments, and post-acute pathways that lower avoidable utilization and improve patient-centered outcomes.